SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
G1 Therapeutics, Inc. (GTHX) , forward earnings yield 142.86%.
Criteria proven by this page:
- VALUE (10/100, Fail) — analyst consensus target implies downside from the current price ($4.50, 37.2%).
- Forward P/E 0.7
- Analyst consensus target $4.50 (-37.2% downside) — analysts see meaningful downside risk at the current price level.
Overall SharesGrow Score: 33/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
10/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — GTHX
Valuation Multiples
P/E (TTM)0.0
Forward P/E0.7
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio4.49
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.93
Forward EPS (Est.)$10.18
Book Value / Share$0.00
Revenue / Share$1.59
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield142.86%
Dividend Yield0.00%
Analyst Target$4.50 (-37.2%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2014 |
$-5.85 |
$1.04M |
$-7.18M |
-688.6% |
| 2015 |
$-0.99 |
$522K |
$-20.26M |
-3881.8% |
| 2016 |
$-1.48 |
$0.00 |
$-30.29M |
- |
| 2017 |
$-3.30 |
$0.00 |
$-60.12M |
- |
| 2018 |
$-2.56 |
$0.00 |
$-85.29M |
- |
| 2019 |
$-3.26 |
$0.00 |
$-122.09M |
- |
| 2020 |
$-2.62 |
$45.29M |
$-99.25M |
-219.2% |
| 2021 |
$-3.54 |
$31.48M |
$-148.35M |
-471.3% |
| 2022 |
$-3.38 |
$51.3M |
$-147.56M |
-287.6% |
| 2023 |
$-0.93 |
$82.51M |
$-47.97M |
-58.1% |
